Centromedian nucleus targeting has evolved significantly since the early days of stereotactic surgery. Initially popularized by Velasco, the centromedian nucleus (CM) of the thalamus has become a primary site for neuromodulation in patients with drug-resistant generalized epilepsy. Precision in electrode placement is vital because it determines which thalamocortical circuits are engaged. Consequently, the field is transitioning from traditional coordinate-based methods to highly individualized, image-guided strategies.

Historically, surgeons relied on indirect measurements and anatomical atlases to locate the CM. While these methods provided a foundation, they often lacked the resolution needed for modern neurostimulation. Therefore, recent efforts like the NAUTILUS trial have introduced standardized workflows. These protocols incorporate advanced MRI sequences to visualize the thalamus with unprecedented clarity. By doing so, clinicians can accommodate complex patient anatomy and ensure consistent placement across different medical centers.

Advanced Imaging in Centromedian Nucleus Targeting

Moreover, the integration of atlas-informed refinements allows for accurate planning even when imaging quality is suboptimal. This evolution is crucial because the CM is small and situated deep within the brain, making it difficult to pinpoint using standard techniques. Research suggests that targeting specific circuits within the CM may lead to better seizure control. Thus, the shift toward personalized surgery represents a major leap in optimizing clinical outcomes for epilepsy patients.

Standardizing these surgical approaches is essential for future data analysis. As neuromodulation gains wider acceptance, a reproducible framework will help clinicians achieve reliable results. The NAUTILUS trial's methodology provides such a framework, offering a robust path forward for location-based outcome analysis. In conclusion, the journey from Velasco’s pioneering work to the current NAUTILUS standards reflects a broader trend toward precision medicine in neurology.

Frequently Asked Questions

Why is the centromedian nucleus difficult to target?

The centromedian nucleus is challenging because of its deep location and small size. Furthermore, it is situated near other critical thalamic structures, requiring high-resolution imaging to distinguish it clearly from its surroundings.

How does the NAUTILUS trial improve surgical outcomes?

The trial introduces a standardized surgical targeting workflow. By using advanced MRI and atlas-based data, it ensures that electrodes are placed accurately in the intended thalamocortical circuits, which enhances both efficacy and reproducibility.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not a substitute for professional medical judgment, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Neudorfer C et al. From Velasco to NAUTILUS: an evolution of centromedian nucleus targeting in epilepsy. J Neurosurg. 2026 May 15. doi: 10.3171/2025.12.JNS252080. PMID: 42139739.

Crudele A. Implant Gives Hope for Idiopathic Generalized Epilepsy - NAUTILUS Trial. Vanderbilt Health. 2022 Oct 6.

Cukiert A, et al. Centromedian thalamic neuromodulation for the treatment of idiopathic generalized epilepsy. Front Neurol. 2022 Aug 2.

American Epilepsy Society. Safety and effectiveness of responsive thalamic stimulation for IGE: NAUTILUS results. AESNET. 2025 Dec 7.